

Breast Cancer Market Research Report 2022 - 2032 | Size, Share and Trend with RISK Analysis

Market Overview:

Global Breast Cancer Market is projected to grow at a staggering CAGR of 9.2% during 2023 and 2032. Breast cancer is a type of cancer developed in breast tissue. Formation of lump in a breast, red patches on the skin are some of the common symptoms of the breast cancer. Obesity, lack of physical exercise, overexposure to radiation and drinking alcohol are some of the risk factors for developing breast cancer.

According to WHO, it is the second most common type of cancer in women. Every year 200,000 new cases are diagnosed worldwide and this number is continuously increasing. Prevalence of breast cancer is more common in developed countries compared to developing countries.

The Key Competitors

Major key players of Global [Breast Cancer Market research](#) are: Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc. (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc. (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), and Bayer AG (Germany).

Increasing number of females suffering from breast cancer is the major factor for the growth of market. Beside this adoption of unhealthy lifestyle, increasing female geriatric population, exposure to harmful radiation and increasing governmental initiatives also contributed in the growth of the market. As no absolute treatment is available there is a scope for developing the market across the world. While on other hand high cost of the treatment, adverse effects associated with the therapy and long approval time for the drugs are responsible for restraining the growth of the market.

Availability of more medicines, new screening tools gaining traction in breast cancer treatment. The biggest change has been the approvals for treatments and available screening tools. Over the last few years, advent breast cancer treatments have hit the market. So the biggest thing that's emerged in the last year that's really impacted the treatment is approval of medications called CDK4/5 Inhibitors. When used in combination with endocrine therapy for patients with hormone-receptor positive breast cancer, the medications have shown improvements in survival – about 10 months. In addition to promising medications, 3-D digital tomosynthesis imaging has gained traction and became available. Mammography allows for a more clear view of the inside of a breast. It's particularly useful to see through dense breast tissue. A signed bill into law that allows commercial insurance providers to cover breast screening, including 3-D mammography.

Breast Cancer Market – Competitive Analysis

Characterized by the presence of several major players, having international recognition; the global market of Breast Cancer appears to be highly fragmented and competitive. Marketers compete based upon price and brand reinforcement. Well established players incorporate acquisition, collaboration, partnership, expansion, and technology launch in order to gain competitive advantage in this market and to maintain their market position.

Breast cancer is the most commonly occurring segment of cancer in women worldwide. The recent reports on cancer confirm the registration of 1.7 million cases of breast cancer. Women populace in

